A Phase 1 Study to Evaluate Sequential Administration of AGN-151586 and Onabotulinumtoxin A (BOTOX) in Subjects for Treatment of Glabellar Lines
Latest Information Update: 12 Jun 2023
At a glance
- Drugs Botulinum toxin E (Primary) ; Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors AbbVie
- 07 Jun 2023 Status changed from active, no longer recruiting to completed.
- 02 Jan 2023 Planned End Date changed from 26 Apr 2023 to 25 May 2023.
- 02 Jan 2023 Planned primary completion date changed from 26 Apr 2023 to 25 May 2023.